MedTrace Logo

Bone Intake Proteins and Muscle Mass Deficiency in Proximal Femur Fractures

NCT05804604 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2023-08-01

No results posted yet for this study

Summary

The aim of this clinical trial is to compare serum concentration of bone intake proteins \[ sex hormone-binding globulin (SHBG), cross linked C-telopeptide of type I collagen (CTX-I)\] and muscle atrophy marker \[creatine kinase (CK-MB)\] between patients after the fracture of proximal femur and their age corresponding counterpart without the fracture. The main question it aims to answer is:

• Is the higher concentration of bone intake proteins and muscle atrophy marker a predictive factor of proximal femur fracture?

The part of participants (Group 1) will be hospitalized at the Department of Orthopaedics and Rehabilitation and will undergo a surgical treatment (open reduction of the fracture). The rest (Group 2) will be admitted to the Department of Internal Medicine. Participants of both Groups will have the blood sample test taken, to evaluate and compare the serum concentration of SHBG, CTX-I and CK-MB proteins.

Conditions

  • Femoral Neck Fractures
  • Pertrochanteric Fracture
  • Bone Resorption
  • Bone Loss
  • Muscle Loss
  • Muscle Damage

Interventions

PROCEDURE

Surgical treatment of proximal femur fracture and blood sample test

Open reduction of femoral neck or pertrochanteric fracture with hemi/total hip arthroplasty or gamma nail. Analysis of serum concentration of: SHBG, CTX - I, CK-MB

PROCEDURE

Blood sample test

Analysis of serum concentration of: SHBG, CTX - I, CK-MB

Sponsors & Collaborators

  • Medical University of Warsaw

    lead OTHER

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-07
Primary Completion
2022-11-29
Completion
2022-11-29

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05804604 on ClinicalTrials.gov